Fig. 4
A) Relative proliferative capacity of MDA-MB-231 cells treated with control (DMEM-F12 without FBS), CM-hUCESCchemo (pre-conditioning of hUCESC with paclitaxel previously of CM production), paclitaxel (1 µM) and the combination of paclitaxel (1 µM) + CM-hUCESCchemo. B) Invasive capacity of MDA-MB-231 cells treated with control (DMEM-F12 without FBS), CM-hUCESCchemo, paclitaxel (1 µM) and the combination of paclitaxel (1 µM) + CM-hUCESCchemo. C) Transmission Electron Microscopy micrographs for control EVs (left) and paclitaxel-loaded EVs (right). (D) Size Distribution graphs by NTA for control EVs and drug loaded EVs. (E) Extracted Ion Chromatogram by HPLC-ESI-TOF at paclitaxel mass/charge for control EVs. (F) Extracted Ion Chromatogram by HPLC-ESI-TOF at paclitaxel mass/charge for drug-loaded EVs. (G) Representative images from mice treated with CM- hUCESCchemo, paclitaxel 5 mg/kg and the combination of paclitaxel 5 mg/kg + CM-hUCESC taken at 7 and 14 days and tumor volume which was determined by measuring luminescence since day 0 until day 21